|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM359352731 |
| 003 |
DE-627 |
| 005 |
20250305004753.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202304122
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1197.xml
|
| 035 |
|
|
|a (DE-627)NLM359352731
|
| 035 |
|
|
|a (NLM)37434421
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Shokouhi, Ali-Reza
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Engineering Efficient CAR-T Cells via Electroactive Nanoinjection
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.11.2023
|
| 500 |
|
|
|a Date Revised 03.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 The Authors. Advanced Materials published by Wiley-VCH GmbH.
|
| 520 |
|
|
|a Chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising cell-based immunotherapy approach for treating blood disorders and cancers, but genetically engineering CAR-T cells is challenging due to primary T cells' sensitivity to conventional gene delivery approaches. The current viral-based method can typically involve significant operating costs and biosafety hurdles, while bulk electroporation (BEP) can lead to poor cell viability and functionality. Here, a non-viral electroactive nanoinjection (ENI) platform is developed to efficiently negotiate the plasma membrane of primary human T cells via vertically configured electroactive nanotubes, enabling efficient delivery (68.7%) and expression (43.3%) of CAR genes in the T cells, with minimal cellular perturbation (>90% cell viability). Compared to conventional BEP, the ENI platform achieves an almost threefold higher CAR transfection efficiency, indicated by the significantly higher reporter GFP expression (43.3% compared to 16.3%). By co-culturing with target lymphoma Raji cells, the ENI-transfected CAR-T cells' ability to effectively suppress lymphoma cell growth (86.9% cytotoxicity) is proved. Taken together, the results demonstrate the platform's remarkable capacity to generate functional and effective anti-lymphoma CAR-T cells. Given the growing potential of cell-based immunotherapies, such a platform holds great promise for ex vivo cell engineering, especially in CAR-T cell therapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a CAR-T cells
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a nano-electroporation
|
| 650 |
|
4 |
|a nanoneedles and nanotubes
|
| 650 |
|
4 |
|a non-viral transfection
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell
|2 NLM
|
| 700 |
1 |
|
|a Chen, Yaping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yoh, Hao Zhe
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brenker, Jason
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Alan, Tuncay
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Murayama, Takahide
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Suu, Koukou
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Morikawa, Yasuhiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Voelcker, Nicolas H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Elnathan, Roey
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 44 vom: 26. Nov., Seite e2304122
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:44
|g day:26
|g month:11
|g pages:e2304122
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202304122
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 44
|b 26
|c 11
|h e2304122
|